Somewhere in Britain today, a patient with a rare cancer or a progressive genetic condition will be told that a drug which could extend or improve their life exists, has been licensed as safe, and is available in France, Germany, and the United States. It is not, however, available on the NHS. The reason is not clinical. It is mathematical.
That calculation is carried out by the National Institute for Health and Care Excellence, the independent body that determines whether new medicines represent sufficient value for the public money spent on them. Since its founding in 1999, NICE has operated according to a framework built on a unit called the Quality-Adjusted Life Year, or QALY. One QALY represents one year of life in perfect health. A drug that extends a patient's life by two years, but in a condition that represents half the quality of full health, generates one QALY. NICE then asks how much the NHS is being asked to pay for each of those QALYs.
For more than two decades, the threshold sat at £30,000 per QALY. Treatments priced above that ceiling were, in most cases, refused routine funding. Patient groups and pharmaceutical companies long argued the figure was arbitrary, set in an era of different medicine and different expectations, and that it had contributed to Britain lagging behind comparable European countries in access to cancer therapies and treatments for rare diseases. In April 2026, the government acted. The threshold has been raised to £35,000 per QALY, the first such increase in twenty years.
The committee that makes these decisions is not composed of ministers or civil servants. It is a mix of clinicians, health economists, and lay members of the public, who meet in private to examine clinical trial data, manufacturer submissions, and evidence from patient groups. Their deliberations are confidential until a final appraisal determination is published. Critics have questioned whether this process is sufficiently transparent; supporters argue the independence it affords is what gives the system credibility.
The April 2026 reforms went further than adjusting the threshold. They introduced a formal power of direction, allowing the Health Secretary to intervene in NICE's methodology on grounds of national health policy. The government has been careful to frame this as distinct from clinical decisions, which will remain with the independent committee. The distinction may prove difficult to maintain under political pressure.
On speed, the reforms also addressed a longstanding bottleneck. Previously, the Medicines and Healthcare products Regulatory Agency assessed whether a drug was safe and effective. Only after a licence was granted did NICE begin its separate appraisal of cost-effectiveness. That sequential process could add six months or more before a drug reached patients. Under a new aligned pathway introduced this year, both bodies now work in parallel, with a target of reducing that delay by three to six months compared with 2025.
Even when NICE recommends a drug, the price that appears in the headlines is rarely what the NHS actually pays. Most approvals are accompanied by confidential commercial access agreements, privately negotiated rebates between NHS England and pharmaceutical manufacturers. The published list price may be well above the threshold; the undisclosed discount brings the effective cost within it. The scale of these arrangements is not made public. A separate mechanism, the Voluntary Scheme for Branded Medicines Pricing, requires the industry to pay rebates to the government when total NHS spending on branded medicines grows beyond an agreed rate.
The system, taken in full, involves rationing. Every decision to fund a high-cost treatment for a specific condition is a decision about priorities within a fixed budget. The money spent on a drug costing £80,000 per patient per year is money not spent on mental health services, waiting list reductions, or primary care. NICE's role is to make that trade-off systematic rather than arbitrary.
Patient organisations have broadly welcomed the April changes. The raised threshold will bring some previously rejected treatments into funding range. Their caution is directed elsewhere: at whether overstretched NHS trusts, infusion units, and specialist clinics have the practical capacity to administer treatments once approved. Approving a drug and delivering it to a patient are not the same thing, and the distance between the two has, in the past, proved longer than the policy intended.
